Inogen (INGN) Cash from Financing Activities (2013 - 2026)
Inogen (INGN) reported Cash from Financing Activities of -$2.1 million for Q1 2026, down 108.86% year-over-year from $24.0 million in Q1 2025, and down 1035.29% quarter-over-quarter from -$187000.0 in Q4 2025.
Inogen (INGN) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Inogen (INGN) has 14 years of Cash from Financing Activities data on file, last reported at -$2.1 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$2.1 million, down 108.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 107.91% YoY), and the FY2025 annual result was $24.2 million, up 9025.28% from the prior year.
- Cash from Financing Activities retreated to -$2.1 million in Q1 2026 per INGN's latest filing, from -$187000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $24.0 million in Q1 2025 and troughed at -$2.1 million in Q1 2026.
- A 5-year average of $1.5 million and a median of -$23500.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities slumped 1757.14% in 2024, then soared 8303.86% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$112000.0 in 2022, then jumped by 87.5% to -$14000.0 in 2023, then tumbled by 1757.14% to -$260000.0 in 2024, then gained by 28.08% to -$187000.0 in 2025, then sank by 1035.29% to -$2.1 million in 2026.
- Business Quant data shows INGN's Cash from Financing Activities at -$2.1 million in Q1 2026, -$187000.0 in Q4 2025, and $418000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -97.90 Mn |
| 10 | Inogen | 176.23 Mn | 81.82 Mn | 37.86 Mn | -2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.12 Mn |
| Mar 31, 2026 | -2.12 Mn |
| Dec 31, 2025 | -187,000.00 |
| Dec 31, 2025 | -187,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Mar 31, 2025 | 23.95 Mn |
| Mar 31, 2025 | 23.95 Mn |
| Dec 31, 2024 | -260,000.00 |
| Dec 31, 2024 | -260,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Mar 31, 2024 | 285,000.00 |
| Mar 31, 2024 | 285,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Sep 30, 2023 | 448,000.00 |
| Sep 30, 2023 | 448,000.00 |